Pure Red-Cell Aplasia and Epoetin Therapy
Top Cited Papers
- 30 September 2004
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 351 (14) , 1403-1408
- https://doi.org/10.1056/nejmoa040528
Abstract
Between 1988 and 1998, antibody-associated pure red-cell aplasia was reported in three patients who had undergone treatment with recombinant human erythropoietin (epoetin). Between 1998 and 2000, 13 such cases were reported from France — 12 in patients who had received the Eprex formulation of epoetin alfa and 1 in a patient who had received Neorecormon (a formulation of epoetin beta); both are products that are marketed outside the United States.Keywords
This publication has 15 references indexed in Scilit:
- Treatment of erythropoietin-induced pure red cell aplasia: a retrospective studyThe Lancet, 2004
- Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here?Nephrology Dialysis Transplantation, 2004
- Anti-Erythropoietin Antibodies and Pure Red Cell AplasiaJournal of the American Society of Nephrology, 2004
- Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS)Nephrology Dialysis Transplantation, 2004
- Dissemination of Information on Potentially Fatal Adverse Drug Reactions for Cancer Drugs From 2000 to 2002: First Results From the Research on Adverse Drug Events and Reports ProjectJournal of Clinical Oncology, 2003
- Pure Red Cell Aplasia Secondary to Treatment with ErythropoietinArtificial Organs, 2003
- Pure Red-Cell Aplasia and Recombinant ErythropoietinNew England Journal of Medicine, 2002
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinNew England Journal of Medicine, 2002
- Subcutaneous Compared with Intravenous Epoetin in Patients Receiving HemodialysisNew England Journal of Medicine, 1998
- Antibodies against Recombinant Human Erythropoietin in a Patient with Erythropoietin-Resistant AnemiaNew England Journal of Medicine, 1996